Healthcare companies by risk reading
Healthcare companies by risk reading: 1,695 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 21 October 2026.
Composite readings for 14,899 companies, recomputed 21 October 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Starling Oncology, Inc. STLN | 39 | Normal | Healthcare | United States | 6 / 6 | $649M |
| Gyre Therapeutics Inc GYRE | 57 | Elevated | Healthcare | United States | 6 / 6 | $646M |
| Pharming Group N.V. PHAR | 31 | Normal | Healthcare | Netherlands | 5 / 6 | $645M |
| Mimedx Group Inc MDXG | 29 | Normal | Healthcare | United States | 5 / 6 | $638M |
| Attovia Therapeutics, Inc. ATTO | 60 | Stretched | Healthcare | United States | 4 / 6 | $634M |
| CK Life Sciences Int'l., (Holdings) Inc. 0775.HK | 69 | Stretched | Healthcare | Hong Kong | 5 / 6 | $625M |
| Inventiva IVA | 82 | Acute | Healthcare | France | 6 / 6 | $619M |
| Medlive Technology Co., Ltd. 2192.HK | 15 | Contained | Healthcare | China | 5 / 6 | $614M |
| Avalo Therapeutics Inc AVTX | 62 | Stretched | Healthcare | United States | 3 / 6 | $613M |
| Wave Life Sciences Ltd WVE | 47 | Elevated | Healthcare | United States | 5 / 6 | $613M |
| Ginkgo Bioworks Holdings Inc - Class A DNA | 59 | Elevated | Healthcare | United States | 5 / 6 | $611M |
| AK Medical Holdings Limited 1789.HK | 31 | Normal | Healthcare | China | 5 / 6 | $607M |
| Zevra Therapeutics Inc ZVRA | 63 | Stretched | Healthcare | United States | 4 / 6 | $603M |
| Anteris Technologies Global Corp AVR | 79 | Stretched | Healthcare | Australia | 6 / 6 | $602M |
| Nanosonics Ltd NAN | 33 | Normal | Healthcare | Australia | 4 / 6 | $602M |
| Beijing Tong Ren Tang Chinese Medicine Company Limited TQR | 36 | Normal | Healthcare | Hong Kong | 5 / 6 | $594M |
| Weave Communications Inc WEAV | 49 | Elevated | Healthcare | United States | 5 / 6 | $591M |
| Ironwood Pharmaceuticals Inc - Class A IRWD | 58 | Elevated | Healthcare | United States | 5 / 6 | $588M |
| RaySearch Laboratories AB (publ) RAY-B | 22 | Normal | Healthcare | Sweden | 5 / 6 | $580M |
| Qol Holdings Co., Ltd. 3034.T | 32 | Normal | Healthcare | Japan | 5 / 6 | $578M |
| OrthoPediatrics Corp KIDS | 62 | Stretched | Healthcare | United States | 6 / 6 | $575M |
| CorMedix Inc CRMD | 28 | Normal | Healthcare | United States | 6 / 6 | $573M |
| Pacific Biosciences of California Inc PACB | 66 | Stretched | Healthcare | United States | 5 / 6 | $572M |
| Phathom Pharmaceuticals Inc PHAT | 72 | Stretched | Healthcare | United States | 5 / 6 | $561M |
| Zeria Pharmaceutical Co., Ltd. 4559.T | 33 | Normal | Healthcare | Japan | 5 / 6 | $560M |
| Cawachi Limited 2664.T | 42 | Elevated | Healthcare | Japan | 5 / 6 | $558M |
| Lumibird SA LBIRD | 38 | Normal | Healthcare | France | 5 / 6 | $556M |
| Fulgent Genetics Inc FLGT | 67 | Stretched | Healthcare | United States | 6 / 6 | $553M |
| Beauty Farm Medical and Health Industry Inc. XC5 | 31 | Normal | Healthcare | China | 5 / 6 | $553M |
| SOPHiA Genetics SA SOPH | 55 | Elevated | Healthcare | Switzerland | 5 / 6 | $552M |
| Integral Diagnostics Limited IDX.AX | 35 | Normal | Healthcare | Australia | 4 / 6 | $551M |
| Xuanzhu Biopharmaceutical Co., Ltd. 2575.HK | 69 | Stretched | Healthcare | China | 4 / 6 | $546M |
| Shattuck Labs Inc STTK | 51 | Elevated | Healthcare | United States | 5 / 6 | $541M |
| GMR Solutions Inc. GMRS | 43 | Elevated | Healthcare | United States | 4 / 6 | $539M |
| DBV Technologies DBVT | 63 | Stretched | Healthcare | France | 5 / 6 | $531M |
| Eiken Chemical Co., Ltd. 4549.T | 50 | Elevated | Healthcare | Japan | 5 / 6 | $525M |
| Valneva SE VALN | 79 | Stretched | Healthcare | France | 5 / 6 | $522M |
| Puma Biotechnology Inc PBYI | 38 | Normal | Healthcare | United States | 5 / 6 | $522M |
| Jacobio Pharmaceuticals Group Co., Ltd. 1167.HK | 67 | Stretched | Healthcare | China | 5 / 6 | $521M |
| Ion Beam Applications SA IBAB | 46 | Elevated | Healthcare | Belgium | 5 / 6 | $519M |
| Shofu Inc. 7979.T | 43 | Elevated | Healthcare | Japan | 4 / 6 | $519M |
| Tactile Systems Technology Inc TCMD | 33 | Normal | Healthcare | United States | 6 / 6 | $516M |
| Genfit S.A. GNFT | 59 | Elevated | Healthcare | France | 5 / 6 | $511M |
| CytomX Therapeutics Inc CTMX | 54 | Elevated | Healthcare | United States | 5 / 6 | $510M |
| Tong Ren Tang Technologies Co. Ltd. 1666.HK | 37 | Normal | Healthcare | China | 5 / 6 | $507M |
| Evolent Health Inc - Class A EVH | 60 | Stretched | Healthcare | United States | 5 / 6 | $505M |
| Evotec SE EVO | 68 | Stretched | Healthcare | Germany | 5 / 6 | $504M |
| Charming Medical Ltd - Class A MCTA | 48 | Elevated | Healthcare | Hong Kong | 5 / 6 | $504M |
| XOMA Corp XOMA | 34 | Normal | Healthcare | United States | 4 / 6 | $504M |
| Ocumension Therapeutics 1477.HK | 48 | Elevated | Healthcare | China | 5 / 6 | $503M |
| Craneware Plc CRW | 27 | Normal | Healthcare | United Kingdom | 5 / 6 | $499M |
| Delcath Systems Inc DCTH | 31 | Normal | Healthcare | United States | 6 / 6 | $498M |
| China Isotope & Radiation Corporation 1763.HK | 43 | Elevated | Healthcare | China | 5 / 6 | $497M |
| SS Innovations International Inc SSII | 63 | Stretched | Healthcare | India | 5 / 6 | $490M |
| Tong Ren Tang Technologies Co. Ltd TNG | 39 | Normal | Healthcare | China | 5 / 6 | $488M |
| Aclaris Therapeutics Inc ACRS | 83 | Acute | Healthcare | United States | 3 / 6 | $487M |
| Evolus Inc EOLS | 58 | Elevated | Healthcare | United States | 5 / 6 | $486M |
| Pharmagest Interactive SA EQS.PA | 48 | Elevated | Healthcare | France | 5 / 6 | $484M |
| Brainsway Ltd BWAY | 28 | Normal | Healthcare | Israel | 5 / 6 | $481M |
| Aquestive Therapeutics Inc AQST | 76 | Stretched | Healthcare | United States | 6 / 6 | $481M |
| OCUMENSION THER.DL-00001 5DG | 50 | Elevated | Healthcare | China | 5 / 6 | $479M |
| Angiodynamic Inc ANGO | 69 | Stretched | Healthcare | United States | 5 / 6 | $475M |
| Arvinas Inc ARVN | 38 | Normal | Healthcare | United States | 5 / 6 | $474M |
| IMPACT Therapeutics, Inc 7630.HK | 60 | Stretched | Healthcare | China | 5 / 6 | $469M |
| GPI S.p.A. GPI.MI | 34 | Normal | Healthcare | Italy | 5 / 6 | $465M |
| Vital KSK Holdings, Inc. 3151.T | 48 | Elevated | Healthcare | Japan | 5 / 6 | $465M |
| Immutep Ltd IMMP | 50 | Elevated | Healthcare | Australia | 4 / 6 | $461M |
| Qyuns Therapeutics Co., Ltd. 2509.HK | 15 | Contained | Healthcare | China | 5 / 6 | $455M |
| National Research Corp NRC | 49 | Elevated | Healthcare | United States | 5 / 6 | $453M |
| Sight Sciences Inc SGHT | 61 | Stretched | Healthcare | United States | 5 / 6 | $452M |
| Egetis Therapeutics AB (publ) EGTX | 67 | Stretched | Healthcare | Sweden | 4 / 6 | $448M |
| Cerus Corp CERS | 58 | Elevated | Healthcare | United States | 5 / 6 | $447M |
| Bayzed Health Group Inc 2609.HK | 38 | Normal | Healthcare | China | 5 / 6 | $447M |
| Shanghai Haohai Biological Technology Co., Ltd. 6826.HK | 41 | Elevated | Healthcare | China | 5 / 6 | $446M |
| Kamada Ltd KMDA | 32 | Normal | Healthcare | Israel | 5 / 6 | $439M |
| Medley, Inc. 4480.T | 27 | Normal | Healthcare | Japan | 5 / 6 | $439M |
| Cogstate Limited CGS.AX | 24 | Normal | Healthcare | Australia | 4 / 6 | $439M |
| Prothena Corporation plc PRTA | 65 | Stretched | Healthcare | Ireland | 4 / 6 | $439M |
| NeuroPace Inc NPCE | 49 | Elevated | Healthcare | United States | 5 / 6 | $438M |
| 908 Devices Inc MASS | 66 | Stretched | Healthcare | United States | 5 / 6 | $435M |
| Altimmune Inc ALT | 53 | Elevated | Healthcare | United States | 5 / 6 | $434M |
| YD Bio Ltd YDES | 64 | Stretched | Healthcare | Taiwan | 5 / 6 | $433M |
| Senseonics Holdings Inc SENS | 55 | Elevated | Healthcare | United States | 6 / 6 | $424M |
| M1 Kliniken AG M12 | 27 | Normal | Healthcare | Germany | 5 / 6 | $423M |
| PolyNovo Limited PNV.AX | 27 | Normal | Healthcare | Australia | 4 / 6 | $423M |
| Autolus Therapeutics plc AUTL | 42 | Elevated | Healthcare | United Kingdom | 5 / 6 | $423M |
| ARS Pharmaceuticals Inc SPRY | 71 | Stretched | Healthcare | United States | 6 / 6 | $421M |
| JCR Pharmaceuticals Co., Ltd. 4552.T | 52 | Elevated | Healthcare | Japan | 5 / 6 | $418M |
| Edding Genor Group Holdings Limited 6998.HK | 36 | Normal | Healthcare | China | 5 / 6 | $413M |
| Cross Country Healthcares Inc CCRN | 61 | Stretched | Healthcare | United States | 5 / 6 | $411M |
| CellaVision AB CEVI | 38 | Normal | Healthcare | Sweden | 4 / 6 | $410M |
| PureTech Health Plc PRTC | 41 | Elevated | Healthcare | United States | 5 / 6 | $408M |
| AVITA Medical Inc RCEL | 54 | Elevated | Healthcare | United States | 6 / 6 | $406M |
| KYORIN Pharmaceutical Co., Ltd. 4569.T | 44 | Elevated | Healthcare | Japan | 5 / 6 | $405M |
| Adicon Holdings Limited 9860.HK | 61 | Stretched | Healthcare | China | 5 / 6 | $405M |
| Myriad Genetics Inc MYGN | 67 | Stretched | Healthcare | United States | 5 / 6 | $402M |
| Strata Critical Medical Inc Cl A Com SRTA | 36 | Normal | Healthcare | United States | 6 / 6 | $402M |
| Ovid Therapeutics Inc OVID | 41 | Elevated | Healthcare | United States | 5 / 6 | $401M |
| Assembly Biosciences Inc ASMB | 54 | Elevated | Healthcare | United States | 6 / 6 | $400M |
| OrbusNeich Medical Group Holdings Limited 6929.HK | 35 | Normal | Healthcare | Hong Kong | 5 / 6 | $399M |
By sector
Industrials 3,117Technology 2,425Consumer Cyclical 2,231Healthcare 1,695Consumer Defensive 1,055Basic Materials 1,055Real Estate 1,011Communication Services 956Energy 487Utilities 343Financial Services 90
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.